company background image
IQAI

IQ-AILSE:IQAI Stock Report

Last Price

UK£0.063

Market Cap

UK£11.4m

7D

-3.8%

1Y

-33.5%

Updated

20 Jan, 2022

Data

Company Financials
IQAI fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

IQAI Stock Overview

IQ-AI Limited, through its subsidiaries, develops software applications for the healthcare industry in Jersey and the United States.

Price History & Performance

Summary of all time highs, changes and price drops for IQ-AI
Historical stock prices
Current Share PriceUK£0.063
52 Week HighUK£0.11
52 Week LowUK£0.052
Beta3.28
1 Month Change13.64%
3 Month Change14.68%
1 Year Change-33.51%
3 Year Change177.78%
5 Year Changen/a
Change since IPO72.41%

Recent News & Updates

Shareholder Returns

IQAIGB Healthcare ServicesGB Market
7D-3.8%-1.8%-0.5%
1Y-33.5%-9.4%8.7%

Return vs Industry: IQAI underperformed the UK Healthcare Services industry which returned -7.8% over the past year.

Return vs Market: IQAI underperformed the UK Market which returned 8.3% over the past year.

Price Volatility

Is IQAI's price volatile compared to industry and market?
IQAI volatility
IQAI Average Weekly Movement7.6%
Healthcare Services Industry Average Movement6.1%
Market Average Movement5.0%
10% most volatile stocks in GB Market10.7%
10% least volatile stocks in GB Market2.5%

Stable Share Price: IQAI is more volatile than 75% of UK stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: IQAI's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a7Trevor Brownhttps://www.imagingbiometrics.com/iq-ai-ltd

IQ-AI Limited, through its subsidiaries, develops software applications for the healthcare industry in Jersey and the United States. Its products include IB Clinic, a toolkit of post-processing software plug-ins for integrating into existing medical image visualization applications; IB Rad Tech, a workflow engine that processes customized workflows; IB Neuro, which analyzes MR data sets and generates parametric perfusion maps quantifying changes in contrast over time; and IB Delta Suite that performs a various fundamental radiology operations, including image co-registration, subtraction, class map generation, and export. The company also offers IB DCE, which analyzes conventional T1 weighted images and generates an array of relevant perfusion and permeability parameters; IB Diffusion that analyzes MR diffusion-weighted images and generates apparent diffusion coefficient, extrapolated b-value, IVIM, and other parameter maps; and StoneChecker, a medical software tool to aid clinical decision making by providing information about a patient’s kidney stone.

IQ-AI Fundamentals Summary

How do IQ-AI's earnings and revenue compare to its market cap?
IQAI fundamental statistics
Market CapUK£11.41m
Earnings (TTM)-UK£561.14k
Revenue (TTM)UK£376.96k

30.3x

P/S Ratio

-20.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IQAI income statement (TTM)
RevenueUK£376.96k
Cost of RevenueUK£7.94k
Gross ProfitUK£369.02k
ExpensesUK£930.16k
Earnings-UK£561.14k

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.0031
Gross Margin97.89%
Net Profit Margin-148.86%
Debt/Equity Ratio0.0%

How did IQAI perform over the long term?

See historical performance and comparison

Valuation

Is IQ-AI undervalued compared to its fair value and its price relative to the market?

13.24x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate IQAI's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate IQAI's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: IQAI is unprofitable, so we can't compare its PE Ratio to the European Healthcare Services industry average.

PE vs Market: IQAI is unprofitable, so we can't compare its PE Ratio to the UK market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IQAI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IQAI is overvalued based on its PB Ratio (13.2x) compared to the GB Healthcare Services industry average (4.4x).


Future Growth

How is IQ-AI forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

29.7%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as IQ-AI has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has IQ-AI performed over the past 5 years?

-21.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IQAI is currently unprofitable.

Growing Profit Margin: IQAI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IQAI is unprofitable, and losses have increased over the past 5 years at a rate of 21.6% per year.

Accelerating Growth: Unable to compare IQAI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IQAI is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (26.7%).


Return on Equity

High ROE: IQAI has a negative Return on Equity (-65.01%), as it is currently unprofitable.


Financial Health

How is IQ-AI's financial position?


Financial Position Analysis

Short Term Liabilities: IQAI's short term assets (£413.7K) exceed its short term liabilities (£356.1K).

Long Term Liabilities: IQAI has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: IQAI is debt free.

Reducing Debt: IQAI currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IQAI has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: IQAI has less than a year of cash runway if free cash flow continues to reduce at historical rates of 14.1% each year


Dividend

What is IQ-AI current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate IQAI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IQAI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IQAI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IQAI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IQAI's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.5yrs

Average board tenure


CEO

Trevor Brown (75 yo)

6.92yrs

Tenure

UK£100,000

Compensation

Mr. Trevor Edward Brown, MBA, serves as a an Executive Director of Strategy & Executive Director at Chamberlin plc and served its Non-Executive Director since 2021. He has been the Chief Executive Officer...


CEO Compensation Analysis

Compensation vs Market: Trevor's total compensation ($USD136.49K) is below average for companies of similar size in the UK market ($USD327.60K).

Compensation vs Earnings: Trevor's compensation has increased whilst the company is unprofitable.


Board Members

Experienced Board: IQAI's board of directors are considered experienced (3.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.3%.


Top Shareholders

Company Information

IQ-AI Limited's employee growth, exchange listings and data sources


Key Information

  • Name: IQ-AI Limited
  • Ticker: IQAI
  • Exchange: LSE
  • Founded: NaN
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Implied Market Cap: UK£11.407m
  • Shares outstanding: 182.51m
  • Website: https://www.imagingbiometrics.com/iq-ai-ltd

Number of Employees


Location

  • IQ-AI Limited
  • Grenville Street
  • Forum 4
  • Saint Helier
  • JE4 8TQ
  • Jersey

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/20 21:15
End of Day Share Price2022/01/20 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.